Filtered library · Theme
Binary-catalyst biotech theme · 68 dossiers
Dossiers in the Binary-catalyst biotech theme cluster — 68 names moving on shared catalysts.
Theme runProduced by the theme run on 20 September 2026, saturated.
All 68 are dated research with a published kill line — the level named in advance that would prove the call wrong.
All dossiers ABSI Absci Corporation fresh MEDIUM Absci Corporation’s valuation rests on ABS-201 delivering human hair-growth efficacy in the guided second half of 2026. Separation from placebo would validate the case; a weekly close below $7.50, absent efficacy or a missed readout window… ALVO Alvotech MEDIUM Alvotech's recovery prices in Q4 2026 FDA approvals after the Reykjavik inspection closure announced on 2026-07-29. AVT05 and AVT06 approvals within that window would confirm the regulatory-repair case; another manufacturing-related… FRNM Freenome, Inc. MEDIUM Freenome's approved blood-test story depends on Abbott launching SimpleScreen CRC and demonstrating reimbursed testing. Carelon's 2026-11-15 guideline strengthens the pathway; a weekly close below $14 or no US launch by 2026-12-31… GHRS GH Research PLC MEDIUM Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next… MANE Veradermics, Incorporated MEDIUM Veradermics’ oral minoxidil story depends on Study ‘304’ replicating the reported hair-growth benefit by year-end 2026. Failed replication, a weekly close below $85, or the reporting window expiring without results would invalidate the… ORKA Oruka Therapeutics, Inc. MEDIUM Supply overhang cleared: the 2026-07-01 Fairmount $300M block at $84.43 was absorbed and price closed $92.70 on 07-17 (+11.6%), 5% off the 52-week high, with 19.85% short interest still rising. Long-acting I&I re-rated by the $10.9B… TARS Tarsus Pharmaceuticals, Inc. MEDIUM Tarsus Pharmaceuticals’ eye-care expansion depends on XDEMVY sustaining growth after the Alkeus acquisition. The case requires next-quarter sales above Q2 2026’s $173.9 million and retention or an increase of both boundaries of the… CLYM Climb Bio, Inc. fresh LOW Climb Bio's re-rating depends on Q4 2026 budoprutug patient data establishing clinical benefit. Recovery of the $17.84 adjusted annual high would confirm the price leg; a weekly close below $13.30 or a delay beyond the guided clinical… IMRN Immuron Limited LOW Immuron’s consumer-health expansion needs a dated US PROIBS launch and disclosed commercial terms to validate its September repricing. The 2026-09-04 agreement supplies neither; a weekly close below $1.65 or an annual report without those… NVAX Novavax, Inc. LOW Novavax's Matrix-M royalty re-rating needs company-confirmed Sanofi trial timing at the 2026-09-09–2026-09-10 conferences. The near-term case fails if both pass without that timing or a weekly close falls below $9.00. SYRE Spyre Therapeutics, Inc. fresh LOW Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs — SPY003 IL-23 Part A (guided mid-2026,… TNGX Tango Therapeutics, Inc. fresh LOW Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17)… ABVX Abivax SA fresh MEDIUM Abivax's recovery case requires a late-2026 obefazimod US filing and a weekly close above the July offering price of $125 by 2026-12-31, before a weekly close below $96 invalidates it. The 2026-09-21 results provide the next scheduled test… AGIO Agios Pharmaceuticals, Inc. fresh MEDIUM Agios Pharmaceuticals' mitapivat label-expansion thesis turns on FDA approval for sickle cell disease by 2026-11-01. Approval would validate the regulatory case; a weekly close below $29 would invalidate the price structure first. DRTS Alpha Tau Medical Ltd. MEDIUM Head-and-neck re-acceleration: a 2026-06-23 first-ex-US glioblastoma treatment drove a +17.9% breakout to new 52-week highs (~$12.56 on 7/11), reclaiming the $11.99 Tolmar equity shelf. The 2026-07-21 AHNS podium with complete Alpha DaRT +… DYN Dyne Therapeutics, Inc. MEDIUM Nothing company-dated until the ~late-October Q3 print, leaving a maturing narrative to trade on small-cap biotech flow ahead of the 2027-01-21 PDUFA. GERN Geron Corporation fresh MEDIUM The leg is a self-funding commercial ramp, not the myelofibrosis binary: Q2 RYTELO revenue $57.5M (+11% QoQ), quarterly cash draw down to ~$14M on $326.9M, FY guide $220–240M reiterated at the mid-to-high end. The 2026-09-02 release added… IVA Inventiva S.A. fresh MEDIUM The 30-day news blackout broke: the 2026-09-02 last-patient-last-visit release in NATiV3 (1,419 patients) reaffirmed Q4 2026 topline and closed the trial-conduct timing gate, leaving database lock and unblinding as the only steps before… MBX MBX Biosciences, Inc. fresh MEDIUM MBX Biosciences' funded once-weekly hormone-replacement program anchors the valuation story, with Q4 2026 obesity data the next clinical test. The price case requires a weekly close above the $70.70 reference high before a weekly close… MIRM Mirum Pharmaceuticals, Inc. fresh MEDIUM Rare-disease franchise ran to a $125 ATH on FOP data, then cooled ~9% into a confirmed 2026-07-30 Q2 print. Base compounds (Q1 sales +43% YoY, FY guide $660–680M) with FOP PDUFA 2026-09-26 and HDV Phase 3 topline 2H26 stacked ahead — but… MNPR Monopar Therapeutics Inc. fresh MEDIUM The rolling-NDA leg rebuilt without news: $107.72 on 2026-08-21 to $117.56 on 2026-09-04, back within 5.1% of the $123.84 high, on no company release since 2026-08-19 and with two directors selling into $109–$113 on 2026-08-25 and… NKTR Nektar Therapeutics fresh MEDIUM M&A read-through re-accelerating: AbbVie's $10.9B Apogee buyout (June 22, 2026) reframed NKTR as the next takeout-able Treg-IL-2 atopic-dermatitis asset, driving a ~25% run off the June low to ~$70. It's sympathy optionality, not fresh… PVLA Palvella Therapeutics, Inc. fresh MEDIUM Palvella Therapeutics’ QTORIN filing puts an accelerated FDA review in focus. Acceptance with Priority Review and a weekly close above $157.77 would complete the case before a weekly close below $137 invalidates it; the filing… RAPP Rapport Therapeutics, Inc. fresh MEDIUM RAPP broke to all-time highs at $42.62 (2026-07-17, +6.2%) on zero company news — the move is pure sell-side re-rating (BTIG reiterated Buy/$65 on 7/16, consensus PT $56.64, 12 desks Strong Buy) with Phase 3 FOCUS now enrolling globally.… TRVI Trevi Therapeutics, Inc. fresh MEDIUM Second breakout leg confirmed: TRVI cleared the June $18.17 all-time high and printed $20.22 on a +9.85% July 17 session (8.3M shares, $19.07 close), lifting the tape ~+45% in six weeks on Phase 3 launch mechanics and institutional… ZBIO Zenas BioPharma, Inc. MEDIUM First-in-disease B-cell modulator: obexelimab BLA (IgG4-RD, 56% flare cut, HR 0.44) hit the FDA 2026-05-28, and the ~60-day filing determination — acceptance plus a possible Priority Review grant — is due within days, a fresh near-term… ALMS Alumis Inc. fresh LOW The lupus leg is gone: LUMUS missed BICLA at Week 48 and every secondary in the overall 408-patient population on 2026-09-01, and the stock closed 2026-09-04 at $11.10 with RSI(14) at 18.2, 63.4% below the $30.30 high. What is left is a… AVTX Avalo Therapeutics, Inc. fresh LOW Avalo Therapeutics' abdakibart recovery case rests on funded Phase 3 development; fuller LOTUS data and a weekly close above the September 4 reference of $19.23 would confirm it. A weekly close below $16 invalidates the case. AVXL Anavex Life Sciences Corp. LOW Anavex Life Sciences’ governance rerating thesis failed its price test: the 2026-09-11 close of $2.62 breached the published $2.75 weekly threshold. The 2026-09-24 board vote still settles control, but it cannot reverse that recorded… BCAX Bicara Therapeutics Inc. LOW Bifunctional EGFR/TGF-β narrative in HPV-negative head & neck cancer stalled after the ASCO 2026 three-year-OS re-rate: $27.76 close is ~10% off the $30.99 high on roughly half prior turnover, consensus PT ~$31.46 sits only 13% above spot,… BHC Bausch Health Companies Inc LOW The post-print round trip is complete: the 2026-07-29 beat-and-raise (adj EPS $1.26 vs $1.04 consensus) carried BHC to a $7.90 high and the 2026-08-28 close of $6.32 handed all of it back. What is left is roughly $2.4B of equity on… BHVN Biohaven Ltd. LOW Biohaven's recovery case rests on SK licence funding and removal of the opakalim enrollment hold. Completion of both and a weekly close above $14 would establish recovery; a daily close below $12.71 invalidates it, while the earlier… CLDX Celldex Therapeutics, Inc. LOW Celldex Therapeutics’ barzolvolimab case requires both Phase 3 CSU trials to meet their primary efficacy endpoints by 2026-10-31 before a weekly close below $35. The 2026-09-11 close of $36.90 leaves the structural case unresolved ahead of… CORT Corcept Therapeutics Incorporated LOW Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry… CRVS Corvus Pharmaceuticals, Inc. LOW Corvus Pharmaceuticals’ soquelitinib recovery case requires a weekly close above the August 28 close of $14.16 before a weekly close below $12.50. Angel’s eczema results, guided on August 6 to late 2026, remain the next clinical test;… DFTX Definium Therapeutics, Inc. LOW Definium Therapeutics’ recovery thesis turns on September’s Panorama anxiety trial confirming DT120 efficacy and restoring the pre-readout price structure. Success requires a positive primary endpoint and a weekly close above $46.14 before… DNTH Dianthus Therapeutics, Inc. LOW Dianthus Therapeutics’ claseprubart re-rating depends on supportive December clinical evidence and a dated pivotal readout. The price case requires a weekly close above $115.96 by 2026-12-31 before a weekly close below $100 invalidates it. DTIL Precision BioSciences, Inc. LOW Precision BioSciences’ hepatitis B gene-editing thesis needs replicated liver-biopsy results by year-end 2026. The case succeeds if additional patients show cccDNA reduction without treatment-limiting safety findings before a weekly close… ELVN Enliven Therapeutics, Inc. LOW Enliven Therapeutics’ re-rating case depends on starting the pivotal ELVN-001 trial within its guided second half of 2026. Disclosed initiation and a weekly close above the $61.15 high recorded on 2026-09-11 would confirm the case before a… ERAS Erasca, Inc. LOW FDA Fast Track for ERAS-0015 in metastatic pancreatic (2026-08-24) landed on 16.4x average volume for a -0.17% close; J.P. Morgan then marked to a street-high $33 on 2026-08-27 while the 2026-08-28 close was $18.03 against a $23.5… HELP Cybin Inc. fresh LOW Post-dilution CNS microcap re-firing with the psychedelic cohort (ATAI, CMPS all moving 2026-07-16) after a June social-velocity blowoff and a 10.3M-share secondary at $4.85. Both covering shops cut targets in July while holding Buy. No… IKT Inhibikase Therapeutics, Inc. fresh LOW Inhibikase Therapeutics’ Phase 3 execution could restore its pulmonary arterial hypertension re-rating. A weekly close above the September 18, 2026 reference high of $2.52 would establish the price case; a weekly close below the July… IMRX Immuneering Corporation fresh LOW Busted-catalyst pancreatic biotech: atebimetinib's 17.3-mo single-arm 1L OS is real, but the Phase 3 binary is mid-2028 and the tape keeps fading post-ASCO ($5.11→$4.32 in two weeks) even as targets climb to $18–$30. Cheap… IMVT Immunovant, Inc. fresh LOW Immunovant’s recovery case depends on IMVT-1402 clinical progress restoring the market’s $44.96 reference high by December 31, 2026. A weekly close below $35 invalidates the case; the September 18 three-month decline and undated clinical… KOD Kodiak Sciences Inc fresh LOW Kodiak Sciences' repricing case rests on September DAYBREAK success and a weekly recovery above the former $36 shelf. Both investigational arms must meet their primary endpoints, while a weekly close below $32 invalidates the setup. LQDA Liquidia Corporation fresh LOW Liquidia Corporation’s recovery case rests on YUTREPIA sales growth and a reclaim of the published $70 shelf. A weekly close above $70 plus next-quarter product sales above Q2 2026’s $170.4 million would confirm the case; a weekly close… LRMR Larimar Therapeutics, Inc. fresh LOW Single-asset FA regulatory binary sitting on the line that defines it: the week ending 2026-09-04 closed $3.83, 0.8% above the twice-tested $3.80 shelf, after five weeks with no company press release since the 2026-08-04 Q2 update. The… MESO Mesoblast Limited fresh LOW Mesoblast’s Ryoncil-funded pipeline thesis faces a sales-growth test at the next quarterly report and weakening price support. A weekly close above the 2026-07-15 high of $18.07 would complete the recovery case; a weekly close below $15… MGNX MacroGenics, Inc. fresh LOW MacroGenics' MGC026 revaluation thesis turns on the 2026-10-23 cancer-data presentation. Cohort-level response and durability evidence followed by a weekly close above $4.86 would confirm the case; a weekly close below $3.90 invalidates it. MRNA Moderna, Inc. fresh LOW Moderna’s cancer-treatment re-rating depends on full INTerpath-001 efficacy data and recovery above the market’s $174.38 event close. A weekly close below $130 invalidates the case; September investor appearances provide dated… NRIX Nurix Therapeutics, Inc. fresh LOW Nurix Therapeutics' Roche-backed bexobrutideg story needs renewed clinical evidence after September's conference window. A weekly close above the $27.79 reference high would confirm the price leg; a weekly close below $24 would invalidate… ORIC Oric Pharmaceuticals, Inc. fresh LOW mCRPC PRC2 story de-risked as rinzimetostat enters registrational Phase 3 (Himalayas-1, 2026-07-14) with Bayer supplying NUBEQA and a J&J-backed enozertinib lung program behind it. But pivotal data is 2028+, so the only near-term mover is… QURE uniQure N.V. fresh LOW FDA's 2026-06-17 reversal put AMT-130 on an accelerated-approval path with a Q3 2026 BLA — the narrative is genuinely repaired, but the move is spent: $40.25 (7/17) sits below the $45.50 June offering price with the CEO selling into it on… RARE Ultragenyx Pharmaceutical Inc. fresh LOW The +50% June reset rally round-tripped from ~$33.46 to $28.62 (2026-07-21), parking price back on the breakout shelf ahead of two binary FDA decisions: DTX401 (GSD Ia) PDUFA Aug 23 and UX111 (Sanfilippo A) PDUFA Sep 19. The July 30 Q2… RCKT Rocket Pharmaceuticals, Inc. fresh LOW Rocket Pharmaceuticals’ Danon recovery case requires clinical progress at the 2026-10-06 webinar and a weekly recovery above $3.86 before a weekly close below $3.20. The September 15 FDA-alignment announcement narrows regulatory… RLMD Relmada Therapeutics, Inc. fresh LOW Relmada Therapeutics’ NDV-01 re-rating thesis was invalidated by the $4.12 weekly close on 2026-09-18, below its published $4.25 shelf. A recovery above the March financing level and an announced IND submission would provide evidence for a… RZLT Rezolute, Inc. fresh LOW The August screener bid fully round-tripped: $5.09 on 2026-08-21 to $4.58 on 2026-09-04, back under the $4.60/$4.61 summer shelf, with no clinical news since 2026-06-17. The registrational upLIFT topline is still guided only to "2H-2026"… SANA Sana Biotechnology, Inc. LOW Type-1-diabetes functional-cure narrative: UP421's no-immunosuppression islet transplant is still producing insulin at 14 months (n=1), de-risking SC451's IND guided "as early as 2026." Rare-disease cell therapy is accelerating, but the… SLDB Solid Biosciences Inc. LOW Solid Biosciences’ SGT-003 thesis depends on functional Duchenne data supporting an accelerated-approval pathway. Favorable disclosed FDA feedback would validate the case; an adverse regulatory outcome or a weekly close below $8.00 would… SLN Silence Therapeutics Plc LOW Silence Therapeutics’ post-readout continuation thesis was invalidated by the 2026-09-11 weekly close of $13.02 below $13.50. Divesiran’s August clinical result remains relevant, but a renewed case requires price recovery and a disclosed… SLS SELLAS Life Sciences Group, Inc. fresh LOW Borrowed sector re-rate has cooled: SLS closed $13.86 on 2026-09-04, 10.3% under the 2026-08-21 high of $15.46, RSI back to 54.1, while REGAL's last published count is still 78 of 80 from 2026-05-11 and BMF Capital's 2026-08-31 short… STRO Sutro Biopharma, Inc. fresh LOW Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June… TENX Tenax Therapeutics, Inc. LOW Tenax Therapeutics’ recovery case depends on FDA acceptance of an enriched LEVEL-2 design after the failed trial’s subgroup signal. An agreed protocol would substantiate the case; a weekly close below $1.70 would invalidate its market… TSHA Taysha Gene Therapies, Inc. fresh LOW De-risking is behind the stock and the calendar in front of it is empty: after the clean 2026-06-22 data and the $6.00 June raise, no company-dated event lands before the ~November Q3 update, and the tape has drifted to a $5.60 close on… VIR Vir Biotechnology, Inc. fresh LOW Q2 (2026-08-05) printed $238.9M revenue and $0.47 diluted EPS on Astellas upfront recognition — an accounting swing, and the tape read it as one: $9.24 on 2026-08-14, still under the $10.36 Astellas equity strike, with Morgan Stanley and… XENE Xenon Pharmaceuticals Inc. LOW Xenon Pharmaceuticals' recovery thesis requires an on-time azetukalner application and a weekly reclaim of the failed $62 shelf. Management guided submission to Q3 2026 on 2026-08-06; a weekly close below $55 or a disclosed filing delay… ZURA Zura Bio Limited LOW Zura Bio’s pipeline-expansion story depends on positive Q4 2026 TibuSHIELD data before a weekly close below $4.90 breaks the setup. The September 11 close of $5.21 and RSI of 39.2 weaken the price evidence; clinical confirmation requires a… ZVRA Zevra Therapeutics, Inc. LOW The June patent re-rating fully reversed: EMA's CHMP issued a negative opinion on arimoclomol's EU application 2026-07-24 (efficacy not proven), and ZVRA gapped ~24% to the high-$9s, cutting through the $11.50 base. EU expansion is now…